economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

subcutaneous

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

creativebharatgroup@gmail.com January 14, 2025
Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today...
Read More Read more about FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia OG_NewsReleaseCompanyLogo_93006.jpg

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

creativebharatgroup@gmail.com December 27, 2024
Osaka, Japan & Cambridge, Mass., United States:   HYQVIA [Immune Globulin Infusion...
Read More Read more about Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

creativebharatgroup@gmail.com October 31, 2024
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B)...
Read More Read more about Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US